SURGE Therapeutics Completes $32 Million Series B Round For Advancing Intraoperative Immunotherapy To Improve Cancer Patient Survival
By Noah Long ● Aug 3, 2023
SURGE Therapeutics - a biotech company pioneering the delivery of immunotherapy during cancer surgery - recently announced the completion of a $32 million Series B financing led by Bioluminescence Ventures, with participation from KdT Ventures, Piedmont Capital, and existing investors 8VC, Alumni Ventures, Camford Capital, Cancer Research Institute, Intuitive Ventures, Khosla Ventures, and Pitango HealthTech.